Peritoneal cancer is a rare cancer that starts in the thin tissue lining the abdomen. Symptoms often appear late and can include abdominal pain, swelling, and feeling full quickly after eating.

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

Zejula can now be used as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk after ...

A companion diagnostic test was simultaneously approved to identify eligible patients whose tumors express PD-L1 with a combined positive score of 1 or higher.

Elahere is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to a cancer medicine. Elahere is used to treat a type ...

Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...

In recent weeks, Merck secured new regulatory milestones for its KEYTRUDA franchise, including U.S. FDA approval for KEYTRUDA and KEYTRUDA QLEX with paclitaxel, with or without bevacizumab, in PD-L1+ ...

First Breakthrough Therapy Designation for Daiichi Sankyo and Merck’s raludotatug deruxtecan based on phase 1 trial and REJOICE-Ovarian01 phase 2/3 trial Second Breakthrough Therapy Designation since ...

The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...